Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting
Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California
Meeting Room
Seaport E-H (Second Level)
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.
Faculty Professor Philippe Moreau, MD
Professor of Clinical Hematology
Head of the Translational Research Program
Hematology and Oncology
University Hospital – CHU de Nantes
Nantes, France
Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Vice Chair, Myeloma Translational Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Moderator Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
This activity is supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting
MODULE 1: Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski
Published findings from the Phase III PERSEUS study supporting the recent FDA approval of daratumumab in combination with RVd as induction and consolidation for transplant-eligible patients with newly diagnosed MM
Key efficacy and safety findings from the Phase III IMROZ and BENEFIT trials of isatuximab in combination with RVd for transplant-ineligible patients with newly diagnosed MM; recent FDA approval of this strategy
Recently presented findings from the Phase III CEPHEUS study evaluating daratumumab/RVd for patients who are transplant ineligible or for whom transplant was not planned as initial therapy
Current role of daratumumab- and isatuximab-containing front-line regimens for patients who are eligible and ineligible for transplant
Recently presented research findings (eg, from the AURIGA, PERSEUS and CASSIOPEIA trials) exploring the role of anti-CD38 monoclonal antibodies as a component of maintenance therapy
MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Richardson
Key findings from the Phase III ICARIA-MM and IKEMA studies of isatuximab in combination with standard doublet regimens; FDA-approved indications for isatuximab for R/R MM
Available data with and ongoing evaluation of subcutaneous formulations of isatuximab
Published efficacy and safety data supporting the use of selinexor in combination with a proteasome inhibitor for patients with R/R MM
Preliminary data with other selinexor-based combination strategies; ongoing Phase III XPORT-MM-031 trial of selinexor/pomalidomide/dexamethasone for patients with R/R MM
Optimal incorporation of selinexor into routine practice and practical considerations with its use, including side-effect mitigation and management
MODULE 3: Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje
Compositional and mechanistic similarities and differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel); implications, if any, for efficacy and tolerability
Research database documenting the effectiveness of ide-cel and cilta-cel for patients with heavily pretreated MM
Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; recently presented overall survival findings with cilta-cel in CARTITUDE-4
Recent FDA approvals of ide-cel and cilta-cel in earlier settings; identification of appropriate candidates for CAR T-cell therapy and optimal sequencing opposite other approaches
Ongoing studies evaluating BCMA-targeted CAR T-cell therapies after induction therapy
Spectrum, incidence and severity of acute and long-term toxicities with CAR T-cell therapy; optimal mitigation and management
Preliminary data and ongoing research with non-BCMA-targeted CAR T-cell platforms
MODULE 4: Bispecific Antibodies for the Treatment of MM — Prof Moreau
Similarities and differences in the cellular targets and mechanisms of action of bispecific antibodies in MM
Available efficacy and safety findings leading to the FDA approvals of the BCMA-directed
bispecific antibodies teclistamab and elranatamab for R/R MM; optimal incorporation into current management algorithms
Available efficacy and safety data supporting the FDA approval of the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of candidates for this agent
Spectrum, incidence and severity of toxicities with BCMA- and non-BCMA-directed bispecific antibodies; optimal mitigation and management strategies
Rationale for and early-phase data with bispecific antibodies in combination with other systemic therapies
MODULE 5: Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial
Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM and rationale for its market withdrawal
Key efficacy and safety findings from Phase III trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone (DREAMM-7) or with pomalidomide/dexamethasone (DREAMM-8) for patients with R/R MM
Spectrum, frequency and severity of toxicities associated with belantamab mafodotin; optimal monitoring and management strategies
Potential role of belantamab mafodotin-based combination strategies in the management of R/R MM
Biological rationale for the evaluation of venetoclax for t(11;14) MM
Early research findings with and ongoing investigation of venetoclax in combination with other systemic agents for MM, such as proteasome inhibitors and anti-CD38 monoclonal antibodies; role outside of a research setting
Mechanism of action of cereblon E3 ligase modulators (CELMoDs), such as iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory drugs
Activity and safety observed with CELMoDs alone and in combination with other agents for patients with pretreated MM
Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma (MM).
Learning Objectives
Upon completion of this activity, participants should be able to
Customize the selection of first-line therapy for newly diagnosed MM, considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
Appreciate trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory MM.
Understand the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
Evaluate the biological rationale for and published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with or participation in a clinical trial of one of these novel agents would be appropriate.
Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in clinical trials.
CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR — Dr Lonial — Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis; Stock Options/Stock — Public Company: TG Therapeutics Inc.
Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Meeting Room
Seaport E-H (Second Level)
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
IN-PERSON Registration
Thank you for your interest in our CME program. At this time online registration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 2:45 PM PT on Friday, December 6th. If you are interested in attending, please visit the registration desk outside the Seaport Ballroom A-D (Level 2) of the Manchester Grand Hyatt San Diego hotel (1 Market Place).
Manchester Grand Hyatt is conveniently located 10 minutes (0.5 mile) walking distance from the San Diego Convention Center, where the 66th ASH Annual Meeting is taking place.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
